FRG1BP: A GPCR Receptor and Signaling Pathway Regulator (G284802)

Target Name: FRG1BP

NCBI ID: G284802

FRG1BP

FRG1BP: A GPCR Receptor and Signaling Pathway Regulator

FRG1BP (FRG1B) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and gastrointestinal tract. It is a member of the G protein-coupled receptor (GPCR) family, which includes over 200 known GPCR genes. Receptor proteins of the GPCR family can bind to specific ligands, thereby triggering a series of signal transduction pathways and participating in a variety of biological processes, such as cell proliferation, differentiation, migration, and apoptosis.

FRG1BP is one of the most promising drug targets identified in the past decade. Its expression has been observed in various diseases, including neurodegenerative disorders, cardiovascular diseases, and gastrointestinal diseases. Additionally, it is involved in several signaling pathways, including the TGF-β pathway, which is involved in cell proliferation, differentiation, and survival.

FRG1BP is a key regulator of the TGF-β pathway in the brain. It has been shown to play a role in the regulation of neuronal stem cell proliferation and differentiation, as well as in the regulation of synaptic plasticity. Additionally, it is involved in the regulation of the inflammatory response and has been shown to play a role in the regulation of pain perception.

FRG1BP is also a regulator of the NF-kappa-B pathway, which is involved in inflammation and cellular signaling. It has been shown to play a role in the regulation of inflammation in the brain and has been implicated in the development of neuroinflammatory diseases.

In addition to its involvement in the TGF-β and NF-kappa-B pathways, FRG1BP is also involved in several other signaling pathways, including the PI3K/AKT signaling pathway, which is involved in cell survival and metabolism.

FRG1BP is a potential drug target because of its involvement in several important signaling pathways. Its expression has been observed in various diseases, including neurodegenerative disorders, cardiovascular diseases, and gastrointestinal diseases. Additionally, its involvement in the TGF-β and NF-kappa-B pathways suggests that it may be a useful target for the treatment of diseases that involve these signaling pathways. Further research is needed to fully understand the role of FRG1BP as a drug target and to develop effective treatments.

Protein Name: FSHD Region Gene 1 Family Member B, Pseudogene

The "FRG1BP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FRG1BP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets